Table 1.

Antitumor effect of Velcade in 5TGM1-eGFP myeloma–bearing mice determined by GFP imaging

Velcade (mg/kg)	Calvariae	Pelves, scapulae, and limbs	Rib cages	Spines	Spleens	Soft tissues
0	100	100	100	100	75	100
0.1	100	100	100	88	75	75
0.5	63	75	50	38	0	38
1*	57	14	29	0	0	43
3†	0	0	0	0	0	0

NOTE: Mice (n = 8 per group) inoculated with 5TGM1-eGFP myeloma cells were treated with or without Velcade at the doses indicated by i.p. injection thrice a week for 4 wks. Immediately after sacrifice, tissues were optically imaged in anteroposterior and posteroanterior orientations as described in Materials and Methods. Data presented represent the percentage of mice in each group with one or more fluorescent foci in both orientations.

^*One mouse in this group died a few days before the end of the experiment.

^†One tumor-bearing mouse in this 3 mg/kg group and one non – tumor-bearing mouse in the control group also receiving 3 mg/kg Velcade died a few days after the start of the experiment (due to toxicity), and thus dose administered was reduced thereafter to 2 mg/kg.